J-STAR

CEO and founding partner Akira Udagawa leads the investment team and chairs the investment committee. Udagawa co-founded J-STAR in 2006 after a career at a global private equity firm. All investment decisions are made by the partnership, with senior partners carrying voting rights on the committee.

J-STAR focuses on Japanese mid-market businesses with enterprise values between JPY 1 billion and JPY 10 billion. This is a deliberate positioning below the radar of global mega-funds and above the micro-cap space. The firm views this segment as the deepest pool of founder-succession opportunities in Japan.

The firm relies on a network of regional Japanese banks, accounting firms, and M&A advisory boutiques that refer succession-driven deals before they reach broad auction processes. Japan has a structural supply of these opportunities: millions of profitable SMEs are owned by founders over age 70 with no family successor, creating a pipeline that J-STAR has cultivated for nearly two decades.

J-STAR invests exclusively in Japan. The firm's entire value proposition — sourcing, operational value creation, and exit execution — is built on domestic networks and Japanese-language capabilities. Portfolio companies may have cross-border operations, but the parent entities are always Japan-domiciled.

The firm invests across manufacturing, distribution and logistics, business services, healthcare, and consumer products. Healthcare services and medical devices have been a particularly active area, with public-record investments including Japan Medical Dynamic Marketing and Tsukui Corporation. J-STAR tends to avoid pure technology and real estate.

J-STAR raises blind-pool, closed-end private equity funds with institutional LP bases that include Japanese regional banks, domestic pension funds, and global fund-of-funds. The firm's most recent flagship, J-STAR Fund IV, closed at approximately JPY 65 billion in 2019. Investors commit to the fund, and the GP draws capital as deals are executed.

J-STAR offers co-investment opportunities to its limited partners on a deal-by-deal basis, particularly for larger transactions that approach or exceed the fund's concentration limits. The firm does not operate a separate co-investment fund, but co-investment is a standard feature of its LP relationships and serves as an alignment mechanism alongside the GP commitment.